

IN THE CLAIMS

Please amend claim 1 to read as follows:

R1
1. (Twice amended) A method for the reduction, treatment, or prevention of at least one adverse effect of radiation dermatitis caused by one or more types of radiation selected from the group consisting of alpha radiation, beta radiation, gamma ray radiation and fluoroscopic radiation, comprising the step of applying to an area of skin which has been or will be exposed to said one or more types of radiation, a topical composition which comprises:

an amount of one or more compounds that inhibit at least one of cell differentiation and cell proliferation, metabolites thereof, and pharmaceutically acceptable salts thereof, which is effective, when administered topically in the topical composition to inhibit at least one of cell differentiation and cell proliferation, and

an effective amount of one or more antioxidants or pharmaceutically acceptable salts thereof,

formulated in a pharmaceutically acceptable carrier for a topical composition.

A copy of claim 1, with amendments shown, is appended hereto.

REMARKS

This amendment is responsive to the Office Action dated November 20, 2002. Claim 1 is amended herein. No new claims are added. Claims 1-11 will be pending in the present application upon entry of the amendments herein.

Information Disclosure Statement

Applicant respectfully renews the request that each item cited in the Information Disclosure Statement (IDS) of February 21, 2002, be considered in the examination of the present application. Applicant notes that, under 37 C.F.R. § 1.98(a)(1), an IDS may include "patents, publications, applications, or **other information** submitted for consideration by the Office ..." [*Emphasis added.*] Assuming *arguendo* that the downloaded items do not meet the definition of a publication, the rule provides that they can nevertheless be considered as "other information." The only requirement appearing in 37 C.F.R. § 1.98 for "other information" is